Competition Watchdog Finds New Target: Overpriced Generics

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6712

2016-01-01

BMJ

Abstract:A spate of hefty fines has sent a clear warning to drug companies. Nigel Hawkes reports

What problem does this paper attempt to address?

Competition Authority Will Investigate Price Hikes of Generic Drugs

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i5849

2016-01-01

BMJ

Abstract:Companies that made huge increases in the prices the NHS pays for out-of-patent medicines are facing an inquiry by the Competition and Markets Authority (CMA).The CMA announced the investigation into “suspected unfair pricing by way of charging excessive prices in the supply of certain pharmaceutical products” without naming any of the companies being investigated. But the Times newspaper, which has run a series of investigative stories about generic drug pricing, reported that Concordia International, one of the companies featured in the stories, had confirmed that it was under investigation.1Concordia, formerly known as AMCo,2 was formed by the private equity …
Upstream solutions for price-gouging on critical generic medicines

Adam R Houston,Reed F Beall,Amir Attaran

DOI: https://doi.org/10.1186/s40545-016-0064-8

2016-05-02

Abstract:Exorbitant price increases for critical off-patent medicines have received considerable media attention in recent months, leading to an investigation by the U.S. Senate. However, much of this attention has focused upon the companies that initiated the price increases, all of whom had recently acquired the drugs in question. Overlooked are upstream interventions with the originators of these drugs to prevent generics trolling in the first place. Using the particular example of Eli Lilly and Company's efforts to divest itself of cycloserine, a flawed process that paved the way for the recent price hike by Rodelis Therapeutics, this article highlights the responsibilities of drug originators, and safeguards to ensure similar rights transfers do not affect ongoing affordable access.
Generic Drugs in the United States: Policies to Address Pricing and Competition

Ravi Gupta,Nilay D. Shah,Joseph S. Ross

DOI: https://doi.org/10.1002/cpt.1314

2019-01-10

Abstract:The cost of prescription drugs in the United States continues to be a source of concern for patients, caregivers, and policymakers. Drug prices typically decline rapidly once generic drugs receive US Food and Drug Administration (FDA) approval and enter the market, but the past decade has witnessed rising costs and shortages of generic drugs. We describe the strategies used by brand-name manufacturers to undermine generic competition and the reasons underlying the price increases of off-patent drugs, some of which continue to lack any competition from generic versions, and others that have increased in price despite having generic versions. We discuss the FDA's role in addressing drug prices and promoting competition, including recent agency policies to modify its process of reviewing generic drug applications and to prioritize applications for off-patent drugs with few competitors. We also examine proposed policy solutions and research areas that could help address the price increases of off-patent drugs.

pharmacology & pharmacy
Drug Company Aspen Faces Probe over Hiking Generic Prices

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.j2417

2017-01-01

Abstract:The European Commission has launched an investigation into increased prices on cancer drugs imposed by Aspen, a South African company. Aspen acquired five drugs from GlaxoSmithKline (GSK) in 2009 in a deal worth $2.2bn (then about £1.4bn) in cash and shares. Aspen increased the UK price of busulfan, a leukaemia drug, from £5.20 to £69.02 a pack. Chlorambucil, also used in leukaemia treatments, rose from £8.36 to £42.87. Margrethe Vestager, the EU’s competition commissioner, said that people depended on drugs “to save or prolong our lives” and that, “when the price of a drug suddenly goes up by several hundred percent, this is something the commission may look at. More specifically, in this case we will be …
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks

Toon van der Gronde,Carin A Uyl-de Groot,Toine Pieters

DOI: https://doi.org/10.1371/journal.pone.0182613

IF: 3.7

2017-08-16

PLoS ONE

Abstract:Context: Recent public outcry has highlighted the rising cost of prescription drugs worldwide, which in several disease areas outpaces other health care expenditures and results in a suboptimal global availability of essential medicines. Method: A systematic review of Pubmed, the Financial Times, the New York Times, the Wall Street Journal and the Guardian was performed to identify articles related to the pricing of medicines. Findings: Changes in drug life cycles have dramatically affected patent medicine markets, which have long been considered a self-evident and self-sustainable source of income for highly profitable drug companies. Market failure in combination with high merger and acquisition activity in the sector have allowed price increases for even off-patent drugs. With market interventions and the introduction of QALY measures in health care, governments have tried to influence drug prices, but often encounter unintended consequences. Patent reform legislation, reference pricing, outcome-based pricing and incentivizing physicians and pharmacists to prescribe low-cost drugs are among the most promising short-term policy options. Due to the lack of systematic research on the effectiveness of policy measures, an increasing number of ad hoc decisions have been made with counterproductive effects on the availability of essential drugs. Future challenges demand new policies, for which recommendations are offered. Conclusion: A fertile ground for high-priced drugs has been created by changes in drug life-cycle dynamics, the unintended effects of patent legislation, government policy measures and orphan drug programs. There is an urgent need for regulatory reform to curtail prices and safeguard equitable access to innovative medicines.
Pfizer Could Face Large Fine over Pricing of Generic Phenytoin

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6401

2016-01-01

BMJ

Abstract:The pharmaceutical company Pfizer could face a fine of millions of pounds from the Competition and Markets Authority (CMA), which has been investigating the prices charged for a generic drug used to treat epilepsy. Court papers seen by the Times shed new light on a deal in which Pfizer agreed to supply the drug to a generic company, Flynn Pharma, at a much greater price than it had been charging the NHS.1 Flynn could then increase the price still further by selling it under the generic name phenytoin sodium. Both companies would benefit, at the cost of the NHS.2 The papers seen by the Times relate to a case brought by another generic company, Tor Generics, which had approached Pfizer with a similar scheme in …
The Travesty of Expensive Insulin

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i2933

2016-01-01

Abstract:A bad precedent for future drug pricing
Choosing Drugs on Price Alone Will Stifle Innovation, Says Report

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6065

2016-01-01

BMJ

Abstract:The NHS in England should not focus exclusively on price when buying medicines, says a new report published by the London School of Economics (LSE).1Doing so risks endangering constructive partnerships between clinicians, NHS managers, and drug companies and conflicts with the government’s aim of balancing affordability with encouraging innovation, the report warned.While the Pharmaceutical Price Regulation Scheme and HM Treasury both seek to strike this balance, the report warned that growing pressure on NHS budgets will encourage cost saving to the detriment of cooperation and innovation.Tender Loving Care? was written by Andrew Bonser, a consultant who has worked for Pfizer and Boots; Panos Kanavos, deputy director of LSE Health; and David Taylor, emeritus professor of pharmaceutical and public health policy at University College London. It was commissioned and funded …
French Authorities Raid Drug Company Offices to Investigate Collusion over Eye Drug

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.g2815

2014-01-01

Abstract:Competition authorities in France have raided the offices of Roche and Novartis and confiscated material in connection with an investigation into alleged collusion over treatment for age related macular degeneration (AMD). The raids are the latest stage in an investigation begun in 2012 at the prompting of the health minister, Marisol Touraine. Novartis markets ranibizumab (Lucentis) in Europe for the treatment of wet AMD, while Roche sells the related cancer drug, bevacizumab (Avastin). The complaint being investigated is that the two companies colluded to prevent the use of the much cheaper Avastin to treat the eye condition. …
Competition Between Brand-Name and Generics--analysis on Pricing of Brand-Name Pharmaceutical.

Ying Kong

DOI: https://doi.org/10.1002/hec.1392

IF: 2.395

2008-01-01

Health Economics

Abstract:The objective of this paper is to provide two-stage game models explaining the 'Generic Competition Paradox' that demonstrates an increase of brand-name drug price in response to generic entry. Under the assumption that there are two groups of consumers who are segmented by their insurance status, high insurance coverage and low insurance coverage consumers, the models indicate that the decisive factor is the market share of the high insurance coverage consumer and the size of cross-substitute factor relative to certain characteristics of market demand. The paper analyses both the case of only true generic entry and the case of pseudo-generic and true generic entry. The models prove that a brand-name price will increase when both the market share of high insurance coverage consumer and the factor of cross-substitute are small. Also, the 'Generic Competition Paradox' more likely occurs in the market where less pseudo-generic products are produced.
Generic Drugs Not as Safe as FDA Wants You to Believe

C. Michael White

DOI: https://doi.org/10.1177/1060028019881692

IF: 3.4628

2019-10-15

Annals of Pharmacotherapy

Abstract:Food and Drug Administration (FDA) rules for the production of prescription drugs are very rigorous and, if followed, guarantees a safe drug supply. For many years, foreign manufacturers have produced substandard generic products and active pharmaceutical ingredients and shipped them into the United States. If the FDA had inspected them with the same rigor as they do domestic manufacturers, they would have found many of these egregious deviations from ethical manufacturing much earlier. Although the FDA is finally stepping up the number of inspections, their current processes still rely on preannounced inspections with long time horizons, so quality issues can be temporarily corrected and documents altered or destroyed.

pharmacology & pharmacy
Antitrust Scrutiny of Excessive Prices in the Pharmaceutical Sector: A Comparative Study of the Italian and UK Experiences

Margherita Colangelo,Claudia Desogus,Margherita Colangelo,Claudia Desogus

DOI: https://doi.org/10.54648/woco2018012

2018-06-01

World Competition

Abstract:Excessive pricing has generally been seen as a problem to be addressed through sector-specific regulation rather than through antitrust intervention. Literature on the issue is divided between scholars calling for an interventionist approach and those supporting a non-interventionist approach on the basis of conflicting rationales. However, recent cases have called attention to the imposition of excessive prices in the pharmaceutical sector. The Aspen and the Flynn cases, in particular, constitute emblematic examples of such practice in the field of off-patent drugs. The analysis of the investigations conducted by national competition authorities in these cases provides some important insights into the controversial issues of ascertaining when antitrust intervention can be considered justified and of determining which methodology may be properly adopted in order to assess whether a drug price is unfairly high.
An empirical study of the impact of generic drug competition on drug market prices in China

Chen Yina,Liu Pengcheng,Nie Haomiao,Cao Yang

DOI: https://doi.org/10.3389/fpubh.2023.1146531

IF: 5.2

2023-05-25

Frontiers in Public Health

Abstract:Introduction: Generic substitution is encouraged to reduce pharmaceutical spending in China, and with incentive policies, the market size of the generic drug continues to rise. To find out how the generic competition affects drug price in this area, this study examines how the quantity of generic drug manufacturers can influence average drug price in the Chinese market. Methods: This study uses a rigorous selection of drugs from the 2021 China's National Reimbursement Drug List (NRDL), and uses drug-level fixed effects regressions to estimate the relationship between competition and price within each drug. Results: We note that drug prices decline with increasing competition in the Chinese market, but not in a perfectly linear manner, with marginal price declines decreasing after the fourth entrant and "rebounding" at subsequent entrants, especially the sixth. Discussion: The findings suggest the importance of maintaining effective competition between suppliers to control prices, and that the government needs to further control generic pricing, especially for late entry generics, to ensure effective competition in the Chinese market.

public, environmental & occupational health
Pfizer is Fined £84m for “exploiting Opportunity” to Hike Price of Phenytoin

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6628

2016-01-01

BMJ

Abstract:The drug giant Pfizer has been fined £84.2m (€99m; $106.8m) by the Competition and Markets Authority (CMA) for charging excessive prices for a drug used by 48 000 UK patients with epilepsy. Flynn Pharma, Pfizer’s partner in a plan to boost prices of phenytoin sodium by 2600%, has been fined £5.2m. Pfizer said that it would appeal the ruling and the record fine, arguing that the drug was making a loss and that the deal provided a way of ensuring a continuing supply. When Flynn launched the drug as a generic—placing it outside the rules that apply to branded drugs—the price charged was 25-40% less than that of another supplier, Pfizer said …
India: regulator's list of 50 substandard drugs raises questions about oversight and manufacturing

Neeta Lal

DOI: https://doi.org/10.1136/bmj.q2149

2024-10-02

BMJ

Abstract:Medical leaders in India have expressed alarm over a drug alert issued by the country's drug regulator that lists 50 products as "not of standard quality."The list, issued by the Central Drugs Standards Control Organization (CDSCO) in August, includes vitamin C tablets, Shelcal, vitamin B complex, vitamin C softgels, Pan-D, paracetamol tablets, the anti-diabetic drug glimepiride, and the high blood pressure medication telmisartan, among others.1Several leading companies, including Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics, Karnataka Antibiotics and Pharmaceuticals, Pure and Cure Healthcare, and Meg Lifesciences, have been named as manufacturers of the medicines. Other companies, including Sun Pharma and Torrent Pharma, claim that medicines flagged in the report are "counterfeits" and that their products conform to quality standards.CDSCO's list is based on random sampling conducted by inspectors. "We randomly test drugs and samples to ensure their quality as well as safety standards. If they don't meet our standard quality guidelines,...

medicine, general & internal
When the price is right: drug costing and NICE approval.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6519

2016-01-01

Abstract:Price discounts are leading to a flurry of NICE approvals. Nigel Hawkes investigatesAfter years of standoffs and angry words, drug companies are cutting prices of cancer treatments in a bid to gain approval for use in the NHS in England.This change of policy, unpredicted when the old Cancer Drugs Fund was wound up in July,1 has analysts puzzled. Has the industry finally recognised that its products are not worth as much as it once claimed? Or is there a subtle plan to clear the decks of unapproved drugs to make room in the revamped Cancer Drugs Fund for yet more expensive ones coming down the pipeline?Whatever the reason, the result has been to allow the National Institute for Health and Care Excellence to approve, at the draft or final guidance stage, seven of the first nine drugs it has reviewed from the old Cancer Drugs Fund list.2 In November NICE approved three drugs for breast cancer in as many weeks and reversed …
When the Price is Right: Drug Costing and NICE Approval

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.i6519

2016-01-01

BMJ

Abstract:Price discounts are leading to a flurry of NICE approvals. Nigel Hawkes investigates
Continuing trends in U.S. brand-name and generic drug competition

Henry Grabowski,Genia Long,Richard Mortimer,Mehmet Bilginsoy

DOI: https://doi.org/10.1080/13696998.2021.1952795

Abstract:Objective: To provide updated evidence in a series of analyses of U.S. trends over the past two decades in key financial metrics for branded drugs: market exclusivity periods (MEPs, the time between launch and first generic entry) for new molecular entities (NMEs); the probability, timing and number of patent challenges under Paragraph IV of the Hatch-Waxman Act; and the intensity of generic penetration. Methods: As previously, we used IQVIA National Sales Perspectives U.S. data to calculate MEPs for the 356 NMEs experiencing initial generic entry from 1995 through 2019, the number of generic competitors for twelve months afterward (by prior sales level), and generic shares. We calculated the probability, timing and number of Paragraph IV challengers using Abbreviated New Drug Application (ANDA) approval letters, the FDA website, public information searches, and ParagraphFour.com. Results: For NMEs experiencing initial generic entry in 2017-19, the MEP was 13.0 years for drugs with sales greater than $250 million in 2008 dollars the year before generic entry (NMEs>$250 million), 14.1 years overall. One year later, brands' average unit share was 18% for NMEs>$250 million, 23% overall. Ninety-three percent of NMEs>$250 million experiencing initial generic entry faced at least one Paragraph IV challenge (2019, three-year rolling average), an average of 6.0 years after brand launch (81% and 6.3 years for all NMEs). NMEs faced an average of 6.8 and 8.9 Paragraph IV challengers per NME, for all and NMEs>$250 million, respectively (2017-19 figures). Limitations: All analyses were restricted to NMEs experiencing generic entry. Conclusion: The average 2017-19 MEP of 13.0 years for NMEs>$250 million has changed relatively little over the past decade and remains lower than for all NMEs (14.1 years). Paragraph IV challenges are more frequent and occur earlier for NMEs>$250 million. Generic share erosion remains high for both NME types.
Nice Sets Cap On Drugs Costing More Than 20m Pound

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.j1372

2017-01-01

Abstract:The Association of the British Pharmaceutical Industry has accused the government of breaking its promise to speed up the introduction of cost effective drugs into the NHS.The association said that proposals by the National Institute for Health and Care Excellence (NICE) and NHS England to refuse to pay for any new drug that will cost more than £20m (€23m; $24m) a year was a breach of a pledge made in the Conservative Party’s election manifesto in 2015.The decision means that new drugs would not only have to meet NICE’s threshold of cost effectiveness—set at about £20 000 to £30 000 …
Generic Drugs and the Struggle to Compete: The Role of Skinny Labels

Marcia M. Boumil,Paul D. Beninger

DOI: https://doi.org/10.1016/j.clinthera.2024.04.007

IF: 3.637

2024-05-27

Clinical Therapeutics

Abstract:Purpose The generic drug industry currently faces multiple, serious issues that threaten the US drug supply. So-called "skinny labels" are one of the few tools authorized by Congress to expedite entry into the market by generic competitors when the first patent for a brand's drug compound (only) expires. This article reviews the law on this expedited marketing pathway for generic competitors, as well as limitations on its use. Methods We examined the literature on patent protection of brand drugs, including the timelines for production of generic competitors. We also examined the law concerning skinny labels, including a recent decision of the US Federal Circuit Court that clearly articulates the guidelines concerning entry into the generic market, including labeling, marketing, and promotion. Findings Skinny labels that follow the regulations set forth in the Hatch-Waxman Act, including the necessary carve-out procedure for "methods of use" still protected by 1 or more active patents, do not infringe a brand drug's label. Furthermore, the skinny label does not induce or contribute to infringement merely because its label contains US Food and Drug Administration–required safety profile data—even when the data cross-reference superiority studies on still-patent protected methods of use elsewhere in the label. Implications Generic drugs have become essential to the broad, general availability of clinical therapeutic agents. The Hatch-Waxman Act was intended to facilitate entry of generic competitors into the marketplace, and the skinny label is an important tool to accomplish that end. As long as the generic manufacturer follows the essential skinny-label rules, specifically including marketing the compound without promoting or advertising those methods of use still protected by ongoing patents, the law will not find induced or contributory infringement.

pharmacology & pharmacy

Competition Watchdog Finds New Target: Overpriced Generics

Competition Authority Will Investigate Price Hikes of Generic Drugs

Upstream solutions for price-gouging on critical generic medicines

Generic Drugs in the United States: Policies to Address Pricing and Competition

Drug Company Aspen Faces Probe over Hiking Generic Prices

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks

Pfizer Could Face Large Fine over Pricing of Generic Phenytoin

The Travesty of Expensive Insulin

Choosing Drugs on Price Alone Will Stifle Innovation, Says Report

French Authorities Raid Drug Company Offices to Investigate Collusion over Eye Drug

Competition Between Brand-Name and Generics--analysis on Pricing of Brand-Name Pharmaceutical.

Generic Drugs Not as Safe as FDA Wants You to Believe

Antitrust Scrutiny of Excessive Prices in the Pharmaceutical Sector: A Comparative Study of the Italian and UK Experiences

An empirical study of the impact of generic drug competition on drug market prices in China

Pfizer is Fined £84m for “exploiting Opportunity” to Hike Price of Phenytoin

India: regulator's list of 50 substandard drugs raises questions about oversight and manufacturing

When the price is right: drug costing and NICE approval.

When the Price is Right: Drug Costing and NICE Approval

Continuing trends in U.S. brand-name and generic drug competition

Nice Sets Cap On Drugs Costing More Than 20m Pound

Generic Drugs and the Struggle to Compete: The Role of Skinny Labels